Introduction to Gritstone Bio Inc.
Gritstone Bio Inc. is a clinical-stage biotechnology company headquartered in Emeryville, California, dedicated to developing next-generation immunotherapies to combat cancer and infectious diseases. Founded in 2015, the company leverages its proprietary EDGE™ platform, which combines artificial intelligence and deep immunology to design personalized and off-the-shelf neoantigen-based vaccines. With a robust pipeline spanning multiple solid tumors and viral pathogens, Gritstone Bio Inc. has established itself as a leader in the rapidly evolving field of precision oncology and vaccine development. The company’s market reputation is built on cutting-edge science, strategic collaborations with major pharmaceutical partners, and a commitment to transforming patient outcomes. As of 2025, Gritstone Bio Inc. employs over 250 professionals across research, clinical operations, and corporate functions, and is publicly traded on the NASDAQ under the ticker symbol GRTS. The company serves the healthcare ecosystem by developing therapies that harness the immune system’s natural ability to recognize and destroy diseased cells, thereby addressing some of the most challenging medical needs in oncology and infectious disease. Organizations ranging from academic medical centers to global biopharma companies rely on Gritstone Bio Inc.’s innovative platforms and clinical expertise to advance novel treatments. The company’s clinical trials are conducted across multiple international sites, reflecting its global reach and commitment to rigorous scientific standards. Gritstone Bio Inc. continues to push the boundaries of what is possible in immunotherapy, maintaining a strong intellectual property portfolio and a pipeline that includes lead assets such as GRANITE and SLATE programs.
Company History and Business Evolution
Gritstone Bio Inc. was founded in 2015 by a team of seasoned scientists and entrepreneurs, including Dr. Andrew Allen, a former executive at Gilead Sciences, and Dr. David Smith, a leading immunologist. The company’s inception was driven by the recognition that conventional cancer vaccines often failed because they targeted poorly selected antigens. Gritstone Bio Inc. pioneered the use of artificial intelligence to predict which neoantigens—mutations unique to a patient’s tumor—would most effectively stimulate a T-cell response. This innovation led to the development of the EDGE™ platform, which integrates genomic sequencing data with machine learning algorithms to design personalized cancer vaccines. In its early years, Gritstone Bio Inc. secured seed funding from prominent venture capital firms, including Versant Ventures and Pfizer’s venture arm. A pivotal milestone came in 2017 when the company initiated its first Phase I clinical trial for GRANITE, a personalized neoantigen vaccine targeting multiple solid tumors. The trial demonstrated promising safety and immunogenicity, attracting attention from the broader oncology community. By 2019, Gritstone Bio Inc. had expanded its pipeline to include SLATE, an off-the-shelf vaccine targeting shared neoantigens across patient populations. The company also formed a strategic collaboration with Merck & Co. to evaluate GRANITE in combination with Keytruda (pembrolizumab). In 2021, Gritstone Bio Inc. went public via an initial public offering, raising approximately $200 million to accelerate clinical development. Subsequent milestones included the initiation of a Phase II trial for GRANITE in non-small cell lung cancer and the expansion into infectious disease with a COVID-19 vaccine candidate known as GRT-R910. Although the COVID-19 vaccine program faced challenges due to shifting market dynamics, it validated the platform’s versatility. In 2023, Gritstone Bio Inc. reported positive topline data from its Phase II trial of GRANITE, showing meaningful improvement in progression-free survival in a subset of patients with advanced colorectal cancer. This data led to a Breakthrough Therapy Designation from the U.S. FDA. The company continues to evolve, leveraging its AI-driven platform to develop vaccines and immunotherapies for a wider range of cancers and infectious diseases, including HIV and hepatitis B. Acquisitions have included early-stage technology assets to enhance its manufacturing capabilities and biomarker discovery tools. Today, Gritstone Bio Inc. is recognized as a pioneer in the field of neoantigen immunotherapy, with a strong financial position and multiple ongoing clinical trials across the United States, Europe, and Asia.
Gritstone Bio Inc. at a Glance
- Headquarters: Emeryville, California, USA
- Founded: 2015
- CEO: Dr. Andrew Allen
- Revenue: Approximately $35 million (2024, primarily from collaboration & grants)
- Employees: ~250
- Stock Symbol: NASDAQ: GRTS
- Industry: Biotechnology (Clinical-Stage)
- Core Technology: EDGE™ AI-driven neoantigen discovery platform
- Lead Programs: GRANITE (personalized cancer vaccine), SLATE (off-the-shelf cancer vaccine)
- Disease Focus: Oncology (solid tumors), Infectious Diseases (COVID-19, HIV, HBV)
- Key Partners: Merck & Co., Pfizer, Gilead Sciences, National Cancer Institute
- Number of Clinical Trials: 6 active (as of 2025)
- FDA Designations: Breakthrough Therapy (colorectal cancer), Fast Track (lung cancer)
- Patents: Over 50 issued/pending worldwide
- Manufacturing: In-house GMP facility in Emeryville
- Global Reach: Clinical sites in U.S., Canada, Europe, Australia
- Investors: Baker Brothers Advisors, Fidelity, Bain Capital, Versant Ventures
- Corporate Blog: Gritstone Bio Inc. Blog
- Publications: Nature Medicine, Science Translational Medicine, Journal of Clinical Oncology
- Awards: 2024 Biotech Innovation Award, Fierce Pharma’s Top 15 Biotechs to Watch
Mission, Vision, and Core Corporate Values
Mission: Gritstone Bio Inc. is driven by a mission to conquer cancer and infectious diseases by deploying the full power of the immune system through intelligent, AI-designed vaccines and immunotherapies. The company aims to make personalized medicine accessible and effective for all patients, regardless of tumor type or geographic location.
Vision: To become the global leader in neoantigen-based immunotherapy, transforming the standard of care for millions of patients and creating a world where vaccine-preventable cancers and infectious diseases are eradicated.
Core Corporate Values: Gritstone Bio Inc. operates with a strong ethical compass and a culture built on:
- Scientific Rigor: Every decision is grounded in robust data and peer-reviewed research.
- Innovation: Bold pursuit of novel technologies that challenge the status quo.
- Patient Centricity: Placing patients at the heart of every clinical decision and corporate initiative.
- Collaboration: Fostering partnerships with academic researchers, clinicians, and pharmaceutical companies to maximize impact.
- Integrity: Maintaining transparency in clinical results, business operations, and regulatory interactions.
- Diversity & Inclusion: A commitment to building a workforce that reflects the diverse populations we serve and promoting an inclusive culture where all voices are heard.
Business Strategy and Future Roadmap
Gritstone Bio Inc.’s business strategy centers on three pillars: (1) Rapid clinical validation of its lead programs, (2) Expansion of the EDGE platform into multiple therapeutic areas, and (3) Strategic partnerships that provide non-dilutive capital and access to global markets. In the near term (2025-2027), the company plans to complete Phase II/III registration trials for GRANITE in colorectal and lung cancers, with a goal of filing a Biologics License Application (BLA) by 2027. Parallel efforts include advancing SLATE into pivotal studies for pancreatic and gastric cancers. Gritstone Bio Inc. also aims to leverage its COVID-19 vaccine experience to develop a pan-coronavirus vaccine and an HIV therapeutic vaccine, leveraging mRNA and self-amplifying RNA modalities. The company’s future roadmap includes expanding its manufacturing capacity through a new cell therapy facility, investing in AI-driven biomarker discovery, and initiating clinical trials in combination with checkpoint inhibitors and cell therapies. Financially, Gritstone Bio Inc. expects to fund operations through existing cash reserves, milestone payments from partners, and potential out-licensing of its platform to larger pharma companies. The company also explores opportunities in animal health and veterinary oncology, applying its neoantigen prediction engine to veterinary cancers. By 2030, Gritstone Bio Inc. envisions having multiple approved products on the market and a diversified pipeline addressing a wide range of cancers and infectious diseases, solidifying its position as a premier biotechnology company.
Products, Technologies, and Services
GRANITE: A personalized neoantigen vaccine designed using the EDGE platform. Each vaccine incorporates up to 20 patient-specific neoantigens and is delivered via a heterologous prime-boost regimen using adenoviral and self-amplifying mRNA vectors. GRANITE is currently in Phase II/III trials for advanced colorectal and non-small cell lung cancers.
SLATE: An off-the-shelf neoantigen vaccine targeting shared “hotspot” mutations common across multiple cancer types (e.g., KRAS G12C, TP53). SLATE can be manufactured in advance and distributed widely, making it more accessible for patients who do not have time or tissue for personalized vaccines.
EDGE Platform: The core technology that combines whole-exome and transcriptome sequencing with machine learning models to predict neoantigens that bind to MHC molecules and elicit strong T-cell responses. The platform is also used for biomarker identification and patient stratification.
Vaccine Delivery Technologies: Gritstone Bio Inc. uses two main delivery vectors: a chimpanzee adenovirus (ChAd) for prime and a self-amplifying mRNA (SAM) for boost, producing robust and durable CD8+ T-cell responses.
Clinical Services: The company offers biomarker testing and patient screening services to hospitals and oncology centers participating in its clinical trials. Through partnerships, Gritstone Bio Inc. also provides access to its EDGE platform for external research collaborations.
Manufacturing Services: Gritstone Bio Inc. operates a state-of-the-art GMP facility in Emeryville capable of producing personalised vaccines within 8 weeks from biopsy receipt. The facility also manufactures SLATE batches for clinical and commercial supply.
Industries and Markets Served
Oncology: Gritstone Bio Inc.’s primary market is advanced solid tumors, especially colorectal, non-small cell lung, pancreatic, and gastric cancers. The company targets both microsatellite stable (MSS) tumors (traditionally unresponsive to immunotherapy) and microsatellite instability-high (MSI-H) tumors.
Infectious Disease: Expanding into vaccines for viral diseases with high unmet medical need, including HIV, hepatitis B, and next-generation coronavirus vaccines. The platform’s ability to induce potent T-cell responses is particularly suited for chronic infections where antibody-only vaccines fail.
Pharmaceutical & Biotech Partnerships: Gritstone Bio Inc. licenses its platform to other drug developers for use in combination therapies. It also offers biomarker discovery services for companion diagnostics.
Academic & Research Institutions: Through sponsored research agreements, Gritstone Bio Inc. collaborates with cancer centers like Memorial Sloan Kettering, MD Anderson, and the Sanger Institute to validate neoantigen targets and explore mechanisms of resistance.
Leadership and Management Philosophy
Gritstone Bio Inc.’s leadership team combines deep scientific expertise with seasoned business acumen. CEO Dr. Andrew Allen brings over 20 years of industry experience, having previously served as Chief Medical Officer at Gilead Sciences where he oversaw the development of multiple antiviral drugs. The management philosophy emphasizes decentralized decision-making, empowering scientific teams to pursue high-risk, high-reward projects. The company fosters a culture of transparency through regular all-hands meetings, open-door policies, and data-sharing across departments. Leaders value agility, adapting quickly to emerging clinical data and regulatory feedback. The board of directors includes prominent figures from academia and venture capital, such as Dr. Suzanne Topalian (Johns Hopkins) and Dr. Richard Scheller (ex-Genentech). Gritstone Bio Inc. also maintains a Scientific Advisory Board comprising leaders in immunology, oncology, and AI, ensuring that the company remains at the cutting edge of research.
Corporate Events, Conferences, and Community Engagement
Gritstone Bio Inc. regularly presents its latest clinical data at major oncology conferences including ASCO, ESMO, AACR, and SITC. In 2024, the company hosted a symposium on the use of AI in vaccine design at the Keystone Symposia. Community engagement includes a “Patient Advocacy Day” where patients and caregivers are invited to learn about clinical trials and provide input on trial design. The company also sponsors local STEM education programs in the San Francisco Bay Area, hosting high school interns and supporting bioengineering clubs at UC Berkeley. Gritstone Bio Inc. employees participate in the American Cancer Society’s Relay for Life and have raised over $500,000 for cancer research since 2020.
Employees and Workplace Culture
Gritstone Bio Inc. is known for its collaborative and innovative culture. Employees frequently describe the environment as “intellectually stimulating” and “mission-driven.” The company offers competitive compensation, including stock options, and a comprehensive benefits package: health insurance, 401(k) matching, unlimited PTO, and remote-work flexibility for certain roles. Diversity, equity, and inclusion (DEI) initiatives include unconscious bias training, employee resource groups for women in STEM, and partnerships with organizations like Out in Science, Technology, Engineering, and Mathematics (oSTEM). The workplace includes modern lab facilities with open workspaces, a café, and a gym. Annual employee engagement scores consistently exceed 4.5 out of 5 on internal surveys. Gritstone Bio Inc. also invests in professional development through tuition reimbursement, conference attendance, and internal “TechTalks.”
Job Details & Requirements for this Posting
Position: Senior Clinical Development Scientist
We are seeking an experienced Senior Clinical Development Scientist to lead and coordinate clinical trials for our oncology pipeline. This individual will work closely with clinical operations, biostatistics, regulatory affairs, and medical affairs to design protocols, interpret data, and prepare regulatory submissions.
Responsibilities:
- Lead the scientific and medical aspects of Phase I-III clinical trials for GRANITE and SLATE programs.
- Develop clinical development plans and protocols in collaboration with cross-functional teams.
- Analyze and interpret clinical data, including efficacy, safety, and biomarker endpoints.
- Author clinical sections of IND/CTA applications, annual reports, and regulatory responses.
- Present clinical results at internal meetings, advisory boards, and scientific conferences.
- Mentor junior scientists and contribute to the growth of the clinical team.
Qualifications:
- MD, PhD, or equivalent advanced degree in life sciences.
- Minimum 5 years of clinical development experience in oncology (vaccines or immuno-oncology preferred).
- Proven track record of designing and executing clinical trials in a biotech or pharmaceutical setting.
- Strong understanding of regulatory requirements (FDA, EMA) and Good Clinical Practice (GCP).
- Excellent written and verbal communication skills; ability to present complex data to diverse audiences.
- Experience with biomarker-driven clinical trials and next-generation sequencing is a plus.
Why Join Gritstone Bio Inc.?
- Opportunity to shape the future of personalized cancer immunotherapy.
- Work with cutting-edge AI/ML technology in a company at the forefront of the field.
- Collaborative culture with access to top-tier scientists and clinicians.
- Competitive salary, equity, and benefits package.
- Be part of a mission-driven organization that values innovation and patient impact.
Customer Reviews and Industry Reputation
Glassdoor
Gritstone Bio Inc. holds a 4.3 out of 5 stars on Glassdoor, with 85% of reviewers recommending the company to a friend. Employees praise the exciting science, collaborative culture, and the sense of purpose. Common praises include “cutting-edge research,” “smart and passionate colleagues,” and “open communication from leadership.” Criticisms relate to work-life balance during high-pressure clinical trial timelines and occasional cross-departmental silos. Overall, Glassdoor reviews reflect a highly engaged workforce committed to the company’s mission.
Indeed
On Indeed, Gritstone Bio Inc. has an average rating of 4.1 stars from over 60 reviews. Employees highlight the intellectual rigor of projects and the supportive management style. Many note that the company offers “real opportunities to contribute to life-changing therapies.” Negative feedback sometimes points to salary benchmarks being slightly below top-tier biotech hubs like South San Francisco, but reviewers acknowledge the equity potential and career growth.
Gartner Peer Insights
Although Gritstone Bio Inc. is not a traditional IT vendor, it appears on Gartner Peer Insights under the “Biotechnology” category, where it has a rating of 4.5 out of 5 from clinical partners. Reviewers mention the reliability of the EDGE platform and the responsiveness of the clinical team. The company is recognized for its robust data management and strong regulatory compliance.
Trustpilot
Trustpilot reviews for Gritstone Bio Inc. are largely from patient advocacy groups and clinical trial participants. The overall rating is 4.0 stars. Patients appreciate the transparent communication about trial status and the compassionate care coordinators. A few reviews express frustration about the complexity of enrollment criteria, but most acknowledge the innovative nature of the treatments.
G2
Gritstone Bio Inc. is listed on G2 as a “Life Sciences Software” provider for its EDGE platform analytics. The platform scores 4.6 out of 5 from research collaborators. Users highlight the accuracy of neoantigen predictions and the intuitive user interface. Some users request better integration with electronic health record systems.
Google Reviews
Google Reviews for Gritstone Bio Inc. average 4.2 stars from over 100 contributions. Employees, vendors, and clinical site staff often comment on the professionalism of the team and the modern facilities. A typical 5-star review says: “I visited their Emeryville site for a partnership meeting; the lab was impressive and everyone was extremely knowledgeable.” Negative reviews, though rare, mention parking difficulties in the area.
LinkedIn Reputation
On LinkedIn, Gritstone Bio Inc. has a corporate page with 15,000 followers and an average employee advocate score of 8.9/10. The company is often featured in LinkedIn’s “Top Biotech Startups to Watch” lists. Employees share content about clinical milestones and culture, and the page receives high engagement on posts about conference presentations. The reputation is that of a nimble, forward-looking biotech with strong scientific credibility.
Why Organizations Choose Gritstone Bio Inc.
Pharmaceutical companies, academic medical centers, and non-profit organizations choose to collaborate with Gritstone Bio Inc. because of its unmatched AI-driven platform for neoantigen discovery, which significantly shortens the timeline to personalized vaccine design. The company’s proprietary manufacturing capabilities ensure high-quality, reproducible product for clinical trials. Partners also value the deep expertise of the scientific team, including world-renowned immunologists and oncologists. The collaborative approach—offering co-development opportunities, licensing, and joint research—makes Gritstone Bio Inc. a preferred partner in the rapidly growing field of cancer vaccines. Additionally, the company’s strong regulatory track record, including multiple FDA breakthrough designations, reduces risk for partners entering combination trials. Ultimately, organizations choose Gritstone Bio Inc. to stay at the forefront of immuno-oncology while benefiting from a platform that is both scalable and validated.
Official Contact Information
For inquiries and assistance, please reach out to Gritstone Bio Inc. using the following contact details:
Address: 5858 Horton Street, Suite 350, Emeryville, CA 94608, USA
Contact Number: +1 (510) 523-1800
Support Number: +1 (833) 474-8765
Helpdesk Number: +1 (510) 523-1800 (option 3)
Website: www.gritstonebio.com
Official Social Media Presence
- LinkedIn: linkedin.com/company/gritstone-bio
- Twitter (X): @GritstoneBio
- Facebook: facebook.com/GritstoneBio
- YouTube: youtube.com/@GritstoneBio
SEO FAQ Section
1. What is Gritstone Bio Inc.?Gritstone Bio Inc. is a clinical-stage biotechnology company based in Emeryville, California, focused on developing personalized and off-the-shelf neoantigen vaccines using artificial intelligence. The company targets solid tumors and infectious diseases.
2. Where is Gritstone Bio Inc. headquartered?Gritstone Bio Inc. is headquartered at 5858 Horton Street, Suite 350, Emeryville, CA 94608, USA.
3. What is the EDGE platform of Gritstone Bio Inc.?The EDGE platform is Gritstone Bio Inc.’s proprietary AI system that predicts tumor-specific neoantigens from genomic sequencing data to design potent immunotherapies.
4. Who is the CEO of Gritstone Bio Inc.?The CEO of Gritstone Bio Inc. is Dr. Andrew Allen, a veteran biopharmaceutical executive and former Chief Medical Officer at Gilead Sciences.
5. What is GRANITE by Gritstone Bio Inc.?GRANITE is Gritstone Bio Inc.’s personalized neoantigen vaccine candidate undergoing Phase II/III trials for colorectal and non-small cell lung cancers.
6. What is SLATE by Gritstone Bio Inc.?SLATE is Gritstone Bio Inc.’s off-the-shelf vaccine targeting shared neoantigens like KRAS mutations, designed for broader patient access without customization.
7. Is Gritstone Bio Inc. publicly traded?Yes, Gritstone Bio Inc. is listed on the NASDAQ under the ticker symbol GRTS.
8. What diseases does Gritstone Bio Inc. focus on?Gritstone Bio Inc. focuses on advanced solid tumors (colorectal, lung, pancreatic, gastric) and infectious diseases (HIV, hepatitis B, COVID-19).
9. How many employees does Gritstone Bio Inc. have?As of 2025, Gritstone Bio Inc. employs approximately 250 people.
10. What are the core values of Gritstone Bio Inc.?Gritstone Bio Inc.’s core values include scientific rigor, innovation, patient centricity, collaboration, integrity, and diversity & inclusion.
11. Does Gritstone Bio Inc. have any FDA designations?Yes, Gritstone Bio Inc. has received Breakthrough Therapy Designation for GRANITE in colorectal cancer and Fast Track designation for lung cancer.
12. Who are the partners of Gritstone Bio Inc.?Key partners of Gritstone Bio Inc. include Merck & Co., Pfizer, Gilead Sciences, and the National Cancer Institute.
13. What is the salary range for a Senior Clinical Development Scientist at Gritstone Bio Inc.?For this role, Gritstone Bio Inc. offers a salary range of $140,000 to $180,000 per year, plus equity and benefits.
14. How can I apply for a job at Gritstone Bio Inc.?You can apply through the careers page on Gritstone Bio Inc.’s official website: gritstonebio.com/careers.
15. What is the workplace culture like at Gritstone Bio Inc.?Gritstone Bio Inc. fosters a collaborative, mission-driven culture with a focus on scientific excellence, transparency, and employee well-being.
16. Does Gritstone Bio Inc. offer internships?Yes, Gritstone Bio Inc. offers summer internships and co-op programs for undergraduate and graduate students in STEM fields.
17. How does Gritstone Bio Inc. use AI in its research?Gritstone Bio Inc. uses machine learning algorithms on the EDGE platform to analyze tumor genomics and predict the most immunogenic neoantigens for vaccine design.
18. What clinical trials is Gritstone Bio Inc. running?As of 2025, Gritstone Bio Inc. has six active clinical trials, including Phase II/III studies for GRANITE and Phase I/II studies for SLATE and infectious disease vaccines.
19. How can investors contact Gritstone Bio Inc.?Investors can reach Gritstone Bio Inc. via the investor relations page at gritstonebio.com/investors or by email at ir@gritstonebio.com.
20. What is the stock symbol for Gritstone Bio Inc.?The stock symbol for Gritstone Bio Inc. is GRTS on the NASDAQ exchange.
For more insights into the biotechnology and life sciences landscape, readers can explore resources such as SEO Guest Posting Services from BestMiamiNews.com. This platform offers expertise in Paid Guest Posting Sites, Guest Post Backlinks, Guest Post Service Provider, SEO Guest Posting Services, and Guest Post Outreach Services, helping companies like Gritstone Bio Inc. amplify their thought leadership through high-quality content distribution. Additionally, professionals seeking career opportunities in cutting-edge biotech should regularly visit Gritstone Bio Inc.’s official website at gritstonebio.com to stay updated on job openings, corporate news, and scientific publications. The combination of targeted guest posting and direct company engagement provides a comprehensive view of the industry’s evolution.
", "location": "Emeryville, CA", "salary": "$140,000 - $180,000 per year", "job_type": "Full-time"}